X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4140) 4140
Publication (240) 240
Book Review (31) 31
Book Chapter (7) 7
Dissertation (6) 6
Book / eBook (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vinorelbine (3007) 3007
humans (2939) 2939
oncology (2723) 2723
female (2085) 2085
aged (1833) 1833
chemotherapy (1811) 1811
middle aged (1673) 1673
male (1514) 1514
vinblastine - analogs & derivatives (1460) 1460
index medicus (1436) 1436
lung neoplasms - drug therapy (1419) 1419
antineoplastic combined chemotherapy protocols - therapeutic use (1417) 1417
adult (1338) 1338
carcinoma, non-small-cell lung - drug therapy (1308) 1308
cisplatin (1082) 1082
vinblastine - administration & dosage (1044) 1044
treatment outcome (986) 986
gemcitabine (868) 868
cancer (865) 865
lung neoplasms - pathology (849) 849
docetaxel (724) 724
paclitaxel (723) 723
antineoplastic combined chemotherapy protocols - adverse effects (712) 712
carcinoma, non-small-cell lung - pathology (704) 704
vinorelbine plus cisplatin (696) 696
neoplasm staging (692) 692
deoxycytidine - analogs & derivatives (622) 622
trial (599) 599
aged, 80 and over (596) 596
respiratory system (587) 587
breast neoplasms - drug therapy (578) 578
non-small cell lung cancer (551) 551
cisplatin - administration & dosage (548) 548
lung cancer (538) 538
survival (530) 530
deoxycytidine - administration & dosage (511) 511
carboplatin (507) 507
lung neoplasms - mortality (503) 503
pharmacology & pharmacy (502) 502
survival rate (479) 479
lung cancer, non-small cell (476) 476
survival analysis (475) 475
carcinoma, non-small-cell lung - mortality (463) 463
vinblastine - adverse effects (460) 460
breast cancer (454) 454
therapy (426) 426
antineoplastic agents - therapeutic use (401) 401
prognosis (395) 395
drug administration schedule (393) 393
combination (389) 389
care and treatment (382) 382
disease-free survival (379) 379
phase-ii trial (371) 371
carcinoma (366) 366
breast neoplasms - pathology (365) 365
randomized-trial (341) 341
medicine & public health (331) 331
phase-ii (330) 330
adjuvant chemotherapy (329) 329
vinblastine - therapeutic use (329) 329
paclitaxel - administration & dosage (328) 328
antineoplastic combined chemotherapy protocols - administration & dosage (321) 321
research (321) 321
hematology, oncology and palliative medicine (311) 311
retrospective studies (301) 301
chemotherapy, adjuvant (291) 291
neoplasm metastasis (288) 288
nsclc (280) 280
non-small-cell lung cancer (276) 276
cell lung-cancer (271) 271
phase-iii trial (271) 271
carboplatin - administration & dosage (270) 270
taxoids - administration & dosage (269) 269
antineoplastic agents, phytogenic - administration & dosage (265) 265
dose-response relationship, drug (255) 255
clinical trials (244) 244
metastasis (242) 242
surgery (237) 237
animals (232) 232
navelbine (230) 230
toxicity (226) 226
follow-up studies (224) 224
radiotherapy (223) 223
disease progression (222) 222
antineoplastic agents, phytogenic - therapeutic use (220) 220
deoxycytidine - adverse effects (213) 213
combined modality therapy (208) 208
capecitabine (205) 205
lung neoplasms - surgery (205) 205
phase-iii (205) 205
doxorubicin (198) 198
drug therapy (197) 197
lung neoplasms - therapy (195) 195
metastatic breast cancer (195) 195
quality of life (195) 195
quality-of-life (193) 193
infusions, intravenous (189) 189
combination chemotherapy (187) 187
randomized trial (187) 187
tumors (186) 186
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3954) 3954
French (98) 98
German (27) 27
Japanese (24) 24
Chinese (23) 23
Spanish (21) 21
Italian (9) 9
Korean (8) 8
Polish (6) 6
Czech (5) 5
Russian (5) 5
Portuguese (2) 2
Arabic (1) 1
Icelandic (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Investigational New Drugs, ISSN 0167-6997, 10/2018, Volume 36, Issue 5, pp. 927 - 932
Journal Article
Clinical and Translational Oncology, ISSN 1699-048X, 4/2019, Volume 21, Issue 4, pp. 459 - 466
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2018, Volume 119, Issue 6, pp. 675 - 682
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 03/2019, Volume 46, Issue 3, pp. 447 - 451
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25, Issue 8, pp. 1462 - 1474
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 03/2019, Volume 83, Issue 3, pp. 493 - 500
PurposeThis study investigated correlations of the clinical outcomes of oral metronomic vinorelbine (VNR) with VNR pharmacokinetics and MDR1... 
MDR1 polymorphisms | Pharmacokinetics | Metronomics | Lung cancer | Vinorelbine | ONCOLOGY | PHARMACOLOGY & PHARMACY | MODEL | ELDERLY-PATIENTS | PHASE-I | CHEMOTHERAPY | SINGLE NUCLEOTIDE POLYMORPHISMS | Lung Neoplasms - drug therapy | Follow-Up Studies | Administration, Metronomic | Humans | Middle Aged | Half-Life | Lung Neoplasms - pathology | Male | Feasibility Studies | Dose-Response Relationship, Drug | Vinorelbine - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Aged, 80 and over | Adult | Female | ATP Binding Cassette Transporter, Subfamily B - genetics | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Severity of Illness Index | Vinorelbine - adverse effects | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Drug-Related Side Effects and Adverse Reactions - etiology | Treatment Outcome | Drug-Related Side Effects and Adverse Reactions - epidemiology | Survival Analysis | ROC Curve | Aged | Polymorphism, Single Nucleotide | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Drug-Related Side Effects and Adverse Reactions - diagnosis | Vinorelbine - pharmacokinetics | Chemotherapy | Metabolites | Patient outcomes | Lung cancer, Small cell | Genetic aspects | Metastasis | Drug therapy | Lung cancer, Non-small cell | Cancer | Toxicity | Non-small cell lung carcinoma | Pharmacology | Regression analysis | Patients | Blood | Cisplatin | Clinical outcomes | Blood levels | Metastases | MDR1 protein | Correlation analysis | Genotypes | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 8, pp. 1573 - 1588
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour.... 
ESMO | Recommendations | Stage III | no | Hematology | Non-small-cell lung cancer | Oncology | Locally advanced | stage III | LONG-TERM SURVIVAL | HYPERFRACTIONATED ACCELERATED RADIOTHERAPY | recommendations | RADIATION-THERAPY | POSITRON-EMISSION-TOMOGRAPHY | VINORELBINE PLUS CISPLATIN | FINE-NEEDLE-ASPIRATION | ONCOLOGY | RANDOMIZED PHASE-III | locally advanced | SURGICAL RESECTION | COMPARING PERIOPERATIVE CHEMOTHERAPY | CONCURRENT CHEMORADIOTHERAPY | non-small-cell lung cancer | Lymph Nodes - pathology | Mediastinum | Humans | Lung Neoplasms - pathology | Tomography, X-Ray Computed | Carcinoma, Non-Small-Cell Lung - diagnosis | Lung - diagnostic imaging | Positron-Emission Tomography | Pneumonectomy | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Multimodal Imaging | Societies, Medical | Vinblastine - analogs & derivatives | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Endoscopic Ultrasound-Guided Fine Needle Aspiration | Bronchoscopy | Carcinoma, Non-Small-Cell Lung - pathology | Lung - pathology | Europe | Carboplatin - administration & dosage | Etoposide - administration & dosage | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Disease Management | Lung Neoplasms - diagnosis | Vinorelbine
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2008, Volume 19, Issue 2, pp. 212 - 222
Journal Article
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 06/2018, Volume 152, pp. 327 - 337
[Display omitted] Metronomic vinorelbine (mVNR) has been described primarily as an antiangiogenic therapy, and no direct effects of mVNR on Non Small Cell Lung... 
NSCLC | Erlotinib | Metronomic vinorelbine | Gefitinib | Synergism
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 08/2019, Volume 15, Issue 22, pp. 2561 - 2569
Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome.... 
breast cancer | Navelbine | COMBINATION | chemotherapy | NAME | vinorelbine | CELL LUNG-CANCER | CAPECITABINE | SINGLE-AGENT | metronomic | PHASE-II TRIAL | ONCOLOGY | INTRAVENOUS VINORELBINE | Phase II trial | WEEKLY IV-VINORELBINE | ERIBULIN MESYLATE | 1ST-LINE
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 150 - 157
Purpose: Response to adjuvant chemotherapy after tumor resection varies widely among patients with non-small cell lung cancer (NSCLC); therefore, it is of... 
METAANALYSIS | VINORELBINE PLUS CISPLATIN | ONCOLOGY | STATISTICS | ADENOCARCINOMA | ERCC1
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 8/2019, Volume 176, Issue 3, pp. 637 - 647
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 2011, Volume 12, Issue 1, pp. 77 - 80
Objective: To evaluate the efficacy and toxicity of cisplatin and vinorelbine (NP) for postoperative adjuvant chemotherapy of completely resected breast... 
Adjuvant chemotherapy | Breast cancer | Cisplatin | Vinorelbine | adjuvant chemotherapy | FIRST-LINE | CYCLOPHOSPHAMIDE | 1ST-LINE CHEMOTHERAPY | DOXORUBICIN | DOCETAXEL | PACLITAXEL | vinorelbine | THERAPY | ONCOLOGY | INTRAVENOUS VINORELBINE | WEEKLY IV-VINORELBINE | cisplatin | CARCINOMA
Journal Article
BIOCHEMICAL PHARMACOLOGY, ISSN 0006-2952, 06/2018, Volume 152, pp. 327 - 337
Metronomic vinorelbine (mVNR) has been described primarily as an antiangiogenic therapy, and no direct effects of mVNR on Non Small Cell Lung Cancer (NSCLC)... 
1ST-LINE TREATMENT | NSCLC | PANCREATIC-CANCER | T790M MUTATION | Metronomic vinorelbine | ORAL VINORELBINE | Synergism | CHEMOTHERAPY | BREAST-CANCER | GROWTH-FACTOR RECEPTOR | Erlotinib | PHASE-I TRIAL | ONCOLOGY RESEARCH GROUP | PHARMACOLOGY & PHARMACY | Gefitinib | ELDERLY-PATIENTS
Journal Article
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 09/2018, Volume 34, Issue 9, pp. 1687 - 1694
Objectives: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after... 
real-world study | Non-small cell lung cancer | survival | adjuvant chemotherapy uptake | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | IMPACT | VINORELBINE PLUS CISPLATIN | INTRAVENOUS VINORELBINE
Journal Article